Loading…
Aprea Therapeutics, Inc. is projected to rise to $1.24 by 2027, a +35% move from its current price of $0.9146. APRE is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $0.8725 | $0.9149 | $0.9594 | +0.04% |
| May 30 | $0.8558 | $0.9153 | $0.9789 | +0.08% |
| May 31 | $0.8433 | $0.9156 | $0.9941 | +0.11% |
| Jun 1 | $0.833 | $0.916 | $1.01 | +0.15% |
| Jun 2 | $0.824 | $0.9163 | $1.02 | +0.19% |
| Jun 3 | $0.816 | $0.9167 | $1.03 | +0.23% |
| Jun 4 | $0.8087 | $0.917 | $1.04 | +0.26% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.8087 | $0.917 | $1.04 | +0.26% |
| Week 2 | $0.7697 | $0.9194 | $1.10 | +0.53% |
| Week 3 | $0.7416 | $0.9219 | $1.15 | +0.80% |
| Week 4 | $0.7189 | $0.9243 | $1.19 | +1.06% |
| Week 5 | $0.6997 | $0.9268 | $1.23 | +1.33% |
| Week 6 | $0.683 | $0.9292 | $1.26 | +1.60% |
| Week 7 | $0.6682 | $0.9317 | $1.30 | +1.87% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tumors with biomarkers and ATRN-119, an ATR inhibitor, which is in Phase 1/2a clinical trial for solid tumor indications.
The company is headquartered in Doylestown, Pennsylvania.
APRE is currently trading with a price of $0.95, a market cap of $11.76M, and a market rank of 5112. This places the stock among small-cap healthcare names with speculative upside potential.
The multi-year price forecast shows an upward trajectory in average price, beginning with 2026 at $0.95 and rising through 2030 ($1.26) and 2050 ($3.81). The sequence of yearly averages includes 2027 $1.31, 2028 $1.34, 2029 $1.43, 2031 $1.20, 2032 $1.38, 2033 $1.66, 2034 $2.08, 2035 $1.98, 2040 $2.88, and 2050 $3.81.
Sentiment shifts from Neutral in 2026 to Bullish from 2027 onward, with forecasted ROIs rising from 0 in 2026 to 37.8 (2027), 41.3 (2028), 50.3 (2029), 32.9 (2030), 26.3 (2031), 45 (2032), 75 (2033), 118.9 (2034), 108.5 (2035), 202.9 (2040), and 300.8 (2050).
A major floor 35.5% below — a decisive break under it would weaken the trend.
The nearest floor, 12.5% below — buyers have tended to step in here.
The nearest ceiling, 9.3% above — a clean break opens room to run.
A major ceiling 20.8% above — clearing it would confirm fresh momentum.
Key APRE support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of APRE market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.921 | Sell | $0.9126 | Buy |
| MA 10 | $0.9001 | Buy | $0.9043 | Buy |
| MA 20 | $0.8824 | Buy | $0.8915 | Buy |
| MA 50 | $0.8354 | Buy | $0.8639 | Buy |
| MA 100 | $0.8178 | Buy | $0.9023 | Buy |
| MA 200 | $1.08 | Sell | $1.15 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 53.10 | Neutral |
| Stoch RSI (14) | 50.17 | Neutral |
| CCI (20) | 47.06 | Neutral |
| Williams %R (14) | -36.11 | Info |
| MACD (12,26,9) | 0.00 | Buy |
| ROC (12) | -6.63 | Sell |
| Bollinger %B (20,2) | 0.65 | Neutral |
| Stochastic %K (14) | 63.89 | Neutral |
| TRIX (15) | 0.29 | Buy |
| Awesome (5,34) | 0.03 | Buy |
| Ultimate (7,14,28) | 50.52 | Neutral |
| Momentum (10) | 0.02 | Buy |
| Aroon Osc (25) | -28.00 | Sell |
| Hull MA (9) | 0.94 | Sell |
| ADX (14) | 9.70 | Neutral |
| ATR (14) | 0.04 | Info |
The near-term technical picture is bullish overall. RSI14 stands at 60, while the 50-day simple moving average sits at $0.8287 and the 200-day simple moving average sits at $1.09. Immediate support is marked at $0.80 and resistance at $1.00, offering a defined range for price action.
The 30-day price range runs from a low of $0.6841 to a high of $1.32, indicating a reasonably wide short-term trading band. Annualized volatility is high at 100%, underscoring elevated risk and potential for rapid swings within the current price framework.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.59 | $0.9146 | $1.44 | 0% | Neutral | |
| $0.9123 | $1.24 | $1.82 | +35% | Bullish | |
| $0.8872 | $1.27 | $1.97 | +39% | Bullish | |
| $0.9152 | $1.37 | $2.21 | +50% | Bullish | |
| $0.7743 | $1.20 | $2.02 | +32% | Bullish | |
| $0.7127 | $1.15 | $1.99 | +26% | Bullish | |
| $0.7883 | $1.32 | $2.35 | +44% | Bullish | |
| $0.8982 | $1.55 | $2.84 | +70% | Bullish | |
| $1.09 | $1.95 | $3.65 | +113% | Bullish | |
| $1.02 | $1.89 | $3.61 | +107% | Bullish | |
| $1.24 | $2.67 | $5.57 | +192% | Bullish | |
| $1.65 | $3.67 | $8.44 | +301% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $0.59 | $0.9146 | $1.08 | +0.00% |
| June 2026 | $0.7383 | $0.8812 | $1.09 | -3.66% |
| July 2026 | $0.7814 | $0.9466 | $1.19 | +7.43% |
| August 2026 | $0.817 | $1.00 | $1.29 | +5.79% |
| September 2026 | $0.795 | $0.9841 | $1.28 | -1.74% |
| October 2026 | $0.8088 | $1.01 | $1.33 | +2.66% |
| November 2026 | $0.8592 | $1.08 | $1.44 | +7.07% |
| December 2026 | $0.8434 | $1.07 | $1.44 | -1.09% |
Click any year to see its month-by-month APRE forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect APRE to range from $0.59 to $1.44 through 2026. The $0.9146 average target implies a 0% move from current prices. A consolidation phase looks the most probable path here.
The APRE price prediction for 2027 points to an average of $1.24 (low $0.9123, high $1.82) — a potential gain of +35% on today's $0.9146. Momentum favours further upside here.
In 2028, APRE is projected to trade between $0.8872 and $1.97, averaging $1.27 — a potential gain of +39% from today's $0.9146. That is up +2% on the projected 2027 average. Buyers look set to stay in control over this stretch.
Aprea Therapeutics, Inc.'s 2029 outlook centres on $1.37, within a $0.9152 to $2.21 range. That is up +8% on the projected 2028 average. That marks a +50% change versus current levels. Momentum favours further upside here.
By 2030, APRE could reach as high as $2.02, with a base case around $1.20 and support toward $0.7743 — roughly +32% from $0.9146. Buyers look set to stay in control over this stretch.
Expect APRE to range from $0.7127 to $1.99 through 2031. The $1.15 average target implies a +26% move from current prices. That is -4% versus the projected 2030 average. Momentum favours further upside here.
The APRE price prediction for 2032 points to an average of $1.32 (low $0.7883, high $2.35) — a potential gain of +44% on today's $0.9146. Buyers look set to stay in control over this stretch.
In 2033, APRE is projected to trade between $0.8982 and $2.84, averaging $1.55 — a potential gain of +70% from today's $0.9146. That is up +18% on the projected 2032 average. Momentum favours further upside here.
Aprea Therapeutics, Inc.'s 2034 outlook centres on $1.95, within a $1.09 to $3.65 range. That is up +26% on the projected 2033 average. That marks a +113% change versus current levels. Buyers look set to stay in control over this stretch.
By 2035, APRE could reach as high as $3.61, with a base case around $1.89 and support toward $1.02 — roughly +107% from $0.9146. Momentum favours further upside here.
Expect APRE to range from $1.24 to $5.57 through 2040. The $2.67 average target implies a +192% move from current prices. That is up +42% on the projected 2035 average. Buyers look set to stay in control over this stretch.
The APRE price prediction for 2050 points to an average of $3.67 (low $1.65, high $8.44) — a potential gain of +301% on today's $0.9146. Momentum favours further upside here.
Investing $1,000 in APRE today (≈ 1,093.374153 APRE) could be worth
$4,012.37
+$3,012.37 (+301%) by 2050 · US Dollar
Based on the average projected APRE price of $3.67 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in APREwould be worth at today's price.
$1,000 invested in APRE on May 27, 2025 (≈ 581.395339 APRE) would be worth
$531.74
-$468.26 (-46.8%) today · 0.53× · US Dollar
Based on a APRE entry price of $1.72 vs. today's $0.9146.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.9 | $1,016.22 | +1.6% |
| 1 month ago | $0.861 | $1,062.25 | +6.2% |
| 3 months ago | $0.88 | $1,039.32 | +3.9% |
| 6 months ago | $1.26 | $725.87 | -27.4% |
| 1 year ago | $1.72 | $531.74 | -46.8% |
| All time (5.0y) ago | $90.6 | $10.09 | -99.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our APRE forecast.
Our base-case forecast reaches $1.80 around 2034.
Implied market cap at $1.80: $22.29M
The multi-year forecast paints an upward trajectory for APRE, with the average price rising from $0.95 in 2026 to $3.81 by 2050. Notable mid-term elevations occur by 2034 (avg $2.08) and 2040 (avg $2.88), before extending to 2050 (avg $3.81). The upside is reflected in the growing max prices across years, such as $3.09 in 2033, $3.96 in 2034, $6.13 in 2040, and $8.76 in 2050.
ROI metrics compound over time, reaching 37.8 in 2027, 41.3 in 2028, 50.3 in 2029, 32.9 in 2030, 26.3 in 2031, 45 in 2032, 75 in 2033, 118.9 in 2034, 108.5 in 2035, 202.9 in 2040, and 300.8 in 2050, all within a bullish sentiment framework from 2027 forward.
These forecasts imply meaningful upside potential but carry inherent uncertainty given the early clinical-stage nature of the assets and the absence of guarantees. The figures provided are estimates and should not be construed as financial advice or guarantees of future results.
Tap a question to reveal the answer.
avg $1.26, min $0.7972, max $2.15, ROI 32.9, sentiment BULLISH.
Forecasts show bullish sentiment from 2027 onward with rising averages and ROI values (e.g., 37.8 in 2027, 50.3 in 2029, 202.9 in 2040, 300.8 in 2050).
Yes. The max forecast prices include $2.15 in 2030 and $3.09 in 2033, with higher peaks such as $3.96 in 2034, $6.13 in 2040, and $8.76 in 2050.
$0.6841 to $1.32.
Current price $0.95; market cap $11.76M.
Aprea Therapeutics, Inc. Community Discussion
0Share your Aprea Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.